Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H10I4NO4.Na.H2O |
Molecular Weight | 816.8671 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.[Na+].N[C@@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C([O-])=O
InChI
InChIKey=ANMYAHDLKVNJJO-LTCKWSDVSA-M
InChI=1S/C15H11I4NO4.Na.H2O/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;;/h1-2,4-5,12,21H,3,20H2,(H,22,23);;1H2/q;+1;/p-1/t12-;;/m0../s1
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | HO |
Molecular Weight | 17.0073 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C15H11I4NO4 |
Molecular Weight | 776.87 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00451Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/dosage/levothyroxine.html
Sources: http://www.drugbank.ca/drugs/DB00451
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/dosage/levothyroxine.html
Levothyroxine (T4) is a synthetically prepared levo isomer of thyroxine, the major hormone secreted from the thyroid gland. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form triiodothyronine (T3) which exerts a broad spectrum of stimulatory effects on cell metabolism. Thyroid hormone increases the metabolic rate of cells of all tissues in the body. In the fetus and newborn, thyroid hormone is important for the growth and development of all tissues including bones and the brain. In adults, thyroid hormone helps to maintain brain function, food metabolism, and body temperature, among other effects. The symptoms of thyroid deficiency relieved by levothyroxine include slow speech, lack of energy, weight gain, hair loss, dry thick skin and unusual sensitivity to cold. Levothyroxine acts like the endogenous thyroid hormone thyroxine (T4, a tetra-iodinated tyrosine derivative). In the liver and kidney, T4 is converted to T3, the active metabolite. In order to increase solubility, the thyroid hormones attach to thyroid hormone binding proteins, thyroxin-binding globulin, and thyroxin-binding prealbumin (transthyretin). Transport and binding to thyroid hormone receptors in the cytoplasm and nucleus then takes place. Thus by acting as a replacement for natural thyroxine, symptoms of thyroxine deficiency are relieved. Levothyroxine is used for use alone or in combination with antithyroid agents to treat hypothyroidism, goiter, chronic lymphocytic thyroiditis, myxedema coma, and stupor.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1860 Sources: http://www.drugbank.ca/drugs/DB00451 |
|||
Target ID: CHEMBL1947 Sources: http://www.drugbank.ca/drugs/DB00451 |
0.136 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Synthroid Approved UseLevothyroxine tablets are used for the following indications:
Hypothyroidism
As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter.
Pituitary TSH Suppression
In the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. Launch Date2002 |
|||
Primary | Synthroid Approved UseLevothyroxine tablets are used for the following indications:
Hypothyroidism
As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter.
Pituitary TSH Suppression
In the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. Launch Date2002 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
76.64 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30153382 |
600 μg single, oral dose: 600 μg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOTHYROXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1764.14 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30153382 |
600 μg single, oral dose: 600 μg route of administration: Oral experiment type: SINGLE co-administered: |
LEVOTHYROXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.2 day |
unknown, unknown |
LEVOTHYROXINE serum | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
7.5 h |
unknown, unknown |
LEVOTHYROXINE serum | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.04% |
unknown, unknown |
LEVOTHYROXINE plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5.7 mg 1 times / day single, oral Studied dose Dose: 5.7 mg, 1 times / day Route: oral Route: single Dose: 5.7 mg, 1 times / day Sources: |
healthy, 22 months n = 1 Health Status: healthy Age Group: 22 months Sex: M Population Size: 1 Sources: |
Other AEs: Hypertension, Tachycardia... Other AEs: Hypertension (grade 1) Sources: Tachycardia (grade 1) |
18 mg 1 times / day single, oral Studied dose Dose: 18 mg, 1 times / day Route: oral Route: single Dose: 18 mg, 1 times / day Sources: |
healthy, 30 months n = 1 Health Status: healthy Age Group: 30 months Sex: M Population Size: 1 Sources: |
Other AEs: Hyperthyroidism, Seizures... |
600 ug 1 times / day single, oral Studied dose Dose: 600 ug, 1 times / day Route: oral Route: single Dose: 600 ug, 1 times / day Sources: |
healthy, mean age 35 years n = 36 Health Status: healthy Age Group: mean age 35 years Sex: M+F Population Size: 36 Sources: |
Disc. AE: Alanine aminotransferase increased... AEs leading to discontinuation/dose reduction: Alanine aminotransferase increased (2.8%) Sources: |
50 ug steady, oral (total daily dose) Dose: 50 ug Route: oral Route: steady Dose: 50 ug Sources: |
unhealthy n = 30 Health Status: unhealthy Condition: Graves Disease Population Size: 30 Sources: |
Other AEs: Atrial fibrillation, Palpitations... Other AEs: Atrial fibrillation (serious, 1 patient) Sources: Palpitations (below serious, 3 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypertension | grade 1 | 5.7 mg 1 times / day single, oral Studied dose Dose: 5.7 mg, 1 times / day Route: oral Route: single Dose: 5.7 mg, 1 times / day Sources: |
healthy, 22 months n = 1 Health Status: healthy Age Group: 22 months Sex: M Population Size: 1 Sources: |
Tachycardia | grade 1 | 5.7 mg 1 times / day single, oral Studied dose Dose: 5.7 mg, 1 times / day Route: oral Route: single Dose: 5.7 mg, 1 times / day Sources: |
healthy, 22 months n = 1 Health Status: healthy Age Group: 22 months Sex: M Population Size: 1 Sources: |
Hyperthyroidism | 18 mg 1 times / day single, oral Studied dose Dose: 18 mg, 1 times / day Route: oral Route: single Dose: 18 mg, 1 times / day Sources: |
healthy, 30 months n = 1 Health Status: healthy Age Group: 30 months Sex: M Population Size: 1 Sources: |
|
Seizures | 18 mg 1 times / day single, oral Studied dose Dose: 18 mg, 1 times / day Route: oral Route: single Dose: 18 mg, 1 times / day Sources: |
healthy, 30 months n = 1 Health Status: healthy Age Group: 30 months Sex: M Population Size: 1 Sources: |
|
Alanine aminotransferase increased | 2.8% Disc. AE |
600 ug 1 times / day single, oral Studied dose Dose: 600 ug, 1 times / day Route: oral Route: single Dose: 600 ug, 1 times / day Sources: |
healthy, mean age 35 years n = 36 Health Status: healthy Age Group: mean age 35 years Sex: M+F Population Size: 36 Sources: |
Palpitations | below serious, 3 patients | 50 ug steady, oral (total daily dose) Dose: 50 ug Route: oral Route: steady Dose: 50 ug Sources: |
unhealthy n = 30 Health Status: unhealthy Condition: Graves Disease Population Size: 30 Sources: |
Atrial fibrillation | serious, 1 patient | 50 ug steady, oral (total daily dose) Dose: 50 ug Route: oral Route: steady Dose: 50 ug Sources: |
unhealthy n = 30 Health Status: unhealthy Condition: Graves Disease Population Size: 30 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/15258100/ |
no | |||
no | ||||
weak | ||||
weak | ||||
yes [IC50 15.4 uM] | ||||
yes [IC50 3.3 uM] | ||||
yes [IC50 4.9 uM] | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes | ||||
Sources: https://go.drugbank.com/drugs/DB00451 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Structure, evolution, and liver-specific expression of sterol 12alpha-hydroxylase P450 (CYP8B). | 1999 Jul |
|
Hypothyroidism presenting as hypercholesterolaemia and simvastatin-induced myositis. | 2000 Dec |
|
The role of selenocysteine 133 in catalysis by the human type 2 iodothyronine deiodinase. | 2000 Dec |
|
Thyroid function of former opioid addicts on naltrexone treatment. | 2001 |
|
[A case of 'hallucination of soliloquy' with hypothyroidism induced Hashimoto disease. Meaning of psychopathological research about symptomatic psychosis]. | 2001 |
|
Short- and long-term results of total vs subtotal thyroidectomies in the surgical treatment of Graves' disease. | 2001 |
|
Plasma concentrations of persistent organochlorines in relation to thyrotropin and thyroid hormone levels in women. | 2001 Apr |
|
Short-term hyperthyroidism followed by transient pituitary hypothyroidism in a very low birth weight infant born to a mother with uncontrolled Graves' disease. | 2001 Apr |
|
[Prescription of thyroid function tests in adults as a function of clinical circumstances and of patient management]. | 2001 Apr 14 |
|
[Timely recognition and treatment of hypothyroidism in pregnant women: benefit for the child]. | 2001 Apr 14 |
|
Development of hypertensive status in NISAG rats reared by normotensive Wistar rats. | 2001 Aug |
|
Hyperthyroidism affects lipid metabolism in lactating and suckling rats. | 2001 Aug |
|
Thyroid hormones and thyroid antibodies in infertile males. | 2001 Aug |
|
Developmental landmarks in offspring of rats exposed singly and in combination to Aroclor 1016 and levothyroxine. | 2001 Aug |
|
Coronary bypass surgery in patients with Sheehan's syndrome. | 2001 Dec |
|
Identification of thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy. | 2001 Feb |
|
Generic substitution: issues for problematic drugs. | 2001 Jan |
|
[Thyroid carcinoma. Diagnosis--nonoperative therapy--after care]. | 2001 Jan 11 |
|
Amantadine-induced cortical myoclonus. | 2001 Jan 23 |
|
Age-related changes of protein- and RNA-synthetic processes in experimental hyper- and hypothyroidism. | 2001 Jul |
|
[High levels of carcinoembryonic antigen in a woman with hypothyroidism]. | 2001 Jun 2 |
|
Suppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: a comparison with other disorders affecting bone metabolism. | 2001 Mar |
|
One-year prophylactic treatment of euthyroid Hashimoto's thyroiditis patients with levothyroxine: is there a benefit? | 2001 Mar |
|
Disorders of growth and puberty in children with non-tumoral hydrocephalus. | 2001 Mar |
|
A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. | 2001 Mar |
|
[Morphological characteristics of placenta and hormonal balance in hyperthyroidism of pregnancy]. | 2001 May-Jun |
|
Use of soy protein supplement and resultant need for increased dose of levothyroxine. | 2001 May-Jun |
|
Treatment of hypothyroidism. | 2001 Nov 15 |
|
Functional evidence for the presence of type II 5'-deiodinase in somatotropes and its adaptive role in hypothyroidism. | 2001 Oct |
|
Abbott files NDA, will continue to distribute synthroid. | 2001 Oct 1 |
|
[Screening for thyroid disease. Occurrence of hypothyroidism and hyperthyroidism in patients admitted to a geriatric department]. | 2001 Oct 8 |
|
Acute aortic dissection associated with Sheehan's syndrome. | 2001 Sep |
|
Molecular cloning and sequence of Sparus aurata skeletal myosin light chains expressed in white muscle: developmental expression and thyroid regulation. | 2001 Sep |
|
[RTH syndrome--resistance to thyroid hormone syndrome]. | 2001 Sep 10 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/levothyroxine.html
Usual Adult Dose for Hypothyroidism
Average full replacement dose: 1.7 mcg/kg/day (e.g., 100 to 125 mcg/day for a 70 kg adult) orally
Older patients may require less than 1 mcg/kg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25447738
Addition of Levothyroxine at concentrations of 100-200 nM rescued rat cerebellar granule neurons (CGNs) from cell death in K5 in a dose-dependent manner. 200 nM T4 was also effective in maintaining the neurites of CGNs in K5.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 00:10:00 GMT 2023
by
admin
on
Sat Dec 16 00:10:00 GMT 2023
|
Record UNII |
B82379R9W0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
23667619
Created by
admin on Sat Dec 16 00:10:00 GMT 2023 , Edited by admin on Sat Dec 16 00:10:00 GMT 2023
|
PRIMARY | |||
|
LEVOTHYROXINE SODIUM MONOHYDRATE
Created by
admin on Sat Dec 16 00:10:00 GMT 2023 , Edited by admin on Sat Dec 16 00:10:00 GMT 2023
|
PRIMARY | Description: An almost white or slightly coloured powder, or a fine, slightly coloured, crystalline powder; odourless. Solubility: Very slightly soluble in water; slightly soluble in ethanol (~750 g/L) TS; practically insoluble in acetone R and ether R. It dissolves in solutions of alkali hydroxides. Category: Thyroid hormone. Storage: Levothyroxine sodium should be kept in a tightly closed container, protected from light.Additional information: Levothyroxine sodium may contain a variable quantity of water of crystallization; anhydrous levothyroxine sodium is hygroscopic.Definition: Levothyroxine sodium contains not less than 97.0% and not more than 101.0% of C15H10I4NNaO4, calculated with reference to the dried substance. | ||
|
31178-59-3
Created by
admin on Sat Dec 16 00:10:00 GMT 2023 , Edited by admin on Sat Dec 16 00:10:00 GMT 2023
|
PRIMARY | |||
|
B82379R9W0
Created by
admin on Sat Dec 16 00:10:00 GMT 2023 , Edited by admin on Sat Dec 16 00:10:00 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |